Evidence map›Paper›PMID 26886874›Full record

ArticleThe British journal of radiology2016

A novel approach to contrast-induced nephrotoxicity: the melatonergic agent agomelatine.

Adem Karaman, Busra Diyarbakir, Irmak Durur-Subasi, Duygu Kose, Asli Özbek-Bilgin, Atilla Topcu, Cemal Gundogdu, Afak Durur-Karakaya, Zafer Bayraktutan, Fatih Alper

Open access · greenAbstract read
In one paragraph

Article in The British journal of radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Adem Karaman1 Department of Radiology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Busra Diyarbakir2 Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Irmak Durur-Subasi3 Department of Radiology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Duygu Kose2 Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Asli Özbek-Bilgin2 Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Atilla Topcu4 Department of Pharmacology, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey.
Cemal Gundogdu5 Department of Pathology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Afak Durur-Karakaya6 Department of Radiology, Istanbul Medipol University, Istanbul, Turkey.
Zafer Bayraktutan7 Department of Biochemistry, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.
Fatih Alper1 Department of Radiology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Atatürk University · TRDışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi · TRErzurum Regional Training and Research Hospital · TRIstanbul Medipol University · TRRecep Tayyip Erdoğan University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study the potential nephroprotective role of agomelatine in rat renal tissue in cases of contrast-induced nephrotoxicity (CIN). The drug's action on the antioxidant system and proinflammatory cytokines, superoxide dismutase (SOD) activity, levels of glutathione (GSH) and malondialdehyde (MDA) and the gene expression of interleukin-6 (IL-6), tumour necrosis factor (TNF)-α and nuclear factor kappa B (NF-κB) was measured. Tubular necrosis and hyaline and haemorrhagic casts were also histopathologically evaluated.

methodsThe institutional ethics and local animal care committees approved the study. Eight groups of six rats were put on the following drug regimens: Group 1: healthy controls, Group 2: GLY (glycerol), Group 3: CM (contrast media--iohexol 10 ml kg(-1)), Group 4: GLY+CM, Group 5: CM+AGO20 (agomelatine 20 mg kg(-1)), Group 6: GLY+CM+AGO20, Group 7: CM+AGO40 (agomelatine 40 mg kg(-1)) and Group 8: GLY+CM+AGO40. The groups were evaluated by one-way analysis of variance and Duncan's multiple comparison test.

resultsAgomelatine administration significantly improved the serum levels of blood urea nitrogen (BUN) and creatinine, SOD activity, GSH and MDA. The use of agomelatine had substantial downregulatory consequences on TNF-α, NF-κB and IL-6 messenger RNA levels. Mild-to-severe hyaline and haemorrhagic casts and tubular necrosis were observed in all groups, except in the healthy group. The histopathological scores were better in the agomelatine treatment groups.

conclusionAgomelatine has nephroprotective effects against CIN in rats. This effect can be attributed to its properties of reducing oxidative stress and inhibiting the secretion of proinflammatory cytokines (NF-κB, TNF-α and IL-6). ADVANCES IN KNOWLEDGE: CIN is one of the most important adverse effects of radiological procedures. Renal failure, diabetes, malignancy, old age and non-steroidal anti-inflammatory drug use pose the risk of CIN in patients. Several clinical studies have investigated ways to avoid CIN. Theophylline/aminophylline, statins, ascorbic acid and iloprost have been suggested for this purpose. Agomelatine is one of the melatonin ligands and is used for affective disorders and has antioxidant features. In this study, we hypothesized that agomelatine could have nephroprotective, antioxidant and anti-inflammatory effects against CIN in rats.

Indexed as

AcetamidesAnimalsContrast MediaCytokinesDisease Models, AnimalFemaleGlutathioneInterleukin-6KidneyMalondialdehydeNaphthalenesNF-kappa BOxidative StressRatsRats, WistarRenal Insufficiency, ChronicAcetamidesagomelatineContrast MediaCytokinesGlutathioneInterleukin-6MalondialdehydeNaphthalenesNF-kappa BSelective Serotonin Reuptake InhibitorsSuperoxide DismutaseTumor Necrosis Factor-alpha

Identifiers

PMID26886874
PMCPMC4985449
OpenAlexW2274777640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.